Key facts
- This page summarizes Steve Aselage's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 May 2022, 20:35.
Steve Aselage - 11 May 2022 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)
- Reporting relationship
- Director
- Issuer ticker
- TVTX
- Reported as of
- 11 May 2022
- Net transaction value
- -$56,457
- SEC form
- 4
- Accepted by SEC
- 12 May 2022, 20:35:33 UTC
- Prior SEC filing
- 02 Mar 2022
- Next SEC filing
- 02 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Elizabeth E. Reed, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Steve Aselage filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 12 May 2022.
Change
- Previous filing in this sequence was filed on 02 Mar 2022.
- Current net transaction value: -$56,457.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TVTX
transaction
Common Stock
Sale
- Transaction value
- $56,457
- Shares
- -2,575
- Change %
- -1.7%
- Price
- $21.92
- Shares after
- 146,919
- Date
- 11 May 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.